Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 3.98
HSKA's Cash to Debt is ranked higher than
53% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. HSKA: 3.98 )
Ranked among companies with meaningful Cash to Debt only.
HSKA' s 10-Year Cash to Debt Range
Min: 0.27  Med: 0.69 Max: No Debt
Current: 3.98
Equity to Asset 0.55
HSKA's Equity to Asset is ranked lower than
58% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. HSKA: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
HSKA' s 10-Year Equity to Asset Range
Min: 0.02  Med: 0.57 Max: 0.78
Current: 0.55
0.02
0.78
Interest Coverage 14.13
HSKA's Interest Coverage is ranked lower than
76% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. HSKA: 14.13 )
Ranked among companies with meaningful Interest Coverage only.
HSKA' s 10-Year Interest Coverage Range
Min: 0.8  Med: 8.80 Max: 26.2
Current: 14.13
0.8
26.2
F-Score: 7
Z-Score: 1.87
M-Score: -2.52
WACC vs ROIC
9.46%
6.02%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 5.32
HSKA's Operating margin (%) is ranked higher than
61% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. HSKA: 5.32 )
Ranked among companies with meaningful Operating margin (%) only.
HSKA' s 10-Year Operating margin (%) Range
Min: -125.26  Med: -1.83 Max: 6.71
Current: 5.32
-125.26
6.71
Net-margin (%) 3.38
HSKA's Net-margin (%) is ranked higher than
61% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. HSKA: 3.38 )
Ranked among companies with meaningful Net-margin (%) only.
HSKA' s 10-Year Net-margin (%) Range
Min: -132.76  Med: -1.53 Max: 42.28
Current: 3.38
-132.76
42.28
ROE (%) 5.87
HSKA's ROE (%) is ranked higher than
61% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. HSKA: 5.87 )
Ranked among companies with meaningful ROE (%) only.
HSKA' s 10-Year ROE (%) Range
Min: -104.28  Med: -2.24 Max: 140.27
Current: 5.87
-104.28
140.27
ROA (%) 3.17
HSKA's ROA (%) is ranked higher than
64% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. HSKA: 3.17 )
Ranked among companies with meaningful ROA (%) only.
HSKA' s 10-Year ROA (%) Range
Min: -69.96  Med: -1.33 Max: 61.02
Current: 3.17
-69.96
61.02
ROC (Joel Greenblatt) (%) 18.42
HSKA's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. HSKA: 18.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HSKA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -176.87  Med: -4.12 Max: 23.5
Current: 18.42
-176.87
23.5
Revenue Growth (3Y)(%) 2.20
HSKA's Revenue Growth (3Y)(%) is ranked lower than
63% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. HSKA: 2.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HSKA' s 10-Year Revenue Growth (3Y)(%) Range
Min: -16.9  Med: 1.15 Max: 10.4
Current: 2.2
-16.9
10.4
EBITDA Growth (3Y)(%) 1.00
HSKA's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. HSKA: 1.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HSKA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.9  Med: -24.60 Max: 27.7
Current: 1
-63.9
27.7
EPS Growth (3Y)(%) 0.80
HSKA's EPS Growth (3Y)(%) is ranked higher than
50% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. HSKA: 0.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HSKA' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -35.60 Max: 7.1
Current: 0.8
0
7.1
» HSKA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

HSKA Guru Trades in Q3 2014

Jim Simons 106,880 sh (+61.99%)
Mario Gabelli 57,500 sh (-0.86%)
» More
Q4 2014

HSKA Guru Trades in Q4 2014

Jim Simons 130,580 sh (+22.17%)
Mario Gabelli 53,000 sh (-7.83%)
» More
Q1 2015

HSKA Guru Trades in Q1 2015

Jim Simons 168,280 sh (+28.87%)
Mario Gabelli 52,400 sh (-1.13%)
» More
Q2 2015

HSKA Guru Trades in Q2 2015

Mario Gabelli 52,400 sh (unchged)
Jim Simons 165,180 sh (-1.84%)
» More
» Details

Insider Trades

Latest Guru Trades with HSKA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 70.08
HSKA's P/E(ttm) is ranked lower than
90% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.70 vs. HSKA: 70.08 )
Ranked among companies with meaningful P/E(ttm) only.
HSKA' s 10-Year P/E(ttm) Range
Min: 0.5  Med: 31.05 Max: 549.09
Current: 70.08
0.5
549.09
Forward P/E 44.05
HSKA's Forward P/E is ranked lower than
85% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.33 vs. HSKA: 44.05 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 73.30
HSKA's PE(NRI) is ranked lower than
90% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. HSKA: 73.30 )
Ranked among companies with meaningful PE(NRI) only.
HSKA' s 10-Year PE(NRI) Range
Min: 0.5  Med: 31.57 Max: 604
Current: 73.3
0.5
604
P/B 3.71
HSKA's P/B is ranked lower than
59% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. HSKA: 3.71 )
Ranked among companies with meaningful P/B only.
HSKA' s 10-Year P/B Range
Min: 0.22  Med: 1.27 Max: 75.45
Current: 3.71
0.22
75.45
P/S 2.40
HSKA's P/S is ranked higher than
59% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. HSKA: 2.40 )
Ranked among companies with meaningful P/S only.
HSKA' s 10-Year P/S Range
Min: 0.12  Med: 0.70 Max: 2.53
Current: 2.4
0.12
2.53
PFCF 361.52
HSKA's PFCF is ranked lower than
97% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.00 vs. HSKA: 361.52 )
Ranked among companies with meaningful PFCF only.
HSKA' s 10-Year PFCF Range
Min: 2.45  Med: 17.40 Max: 463
Current: 361.52
2.45
463
POCF 90.39
HSKA's POCF is ranked lower than
92% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.49 vs. HSKA: 90.39 )
Ranked among companies with meaningful POCF only.
HSKA' s 10-Year POCF Range
Min: 2.36  Med: 20.92 Max: 496.33
Current: 90.39
2.36
496.33
EV-to-EBIT 42.84
HSKA's EV-to-EBIT is ranked lower than
82% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.91 vs. HSKA: 42.84 )
Ranked among companies with meaningful EV-to-EBIT only.
HSKA' s 10-Year EV-to-EBIT Range
Min: -122.2  Med: 20.30 Max: 164.2
Current: 42.84
-122.2
164.2
Shiller P/E 146.67
HSKA's Shiller P/E is ranked lower than
98% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.93 vs. HSKA: 146.67 )
Ranked among companies with meaningful Shiller P/E only.
HSKA' s 10-Year Shiller P/E Range
Min: 1.88  Med: 6.30 Max: 155.64
Current: 146.67
1.88
155.64
Current Ratio 2.11
HSKA's Current Ratio is ranked lower than
59% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. HSKA: 2.11 )
Ranked among companies with meaningful Current Ratio only.
HSKA' s 10-Year Current Ratio Range
Min: 1.03  Med: 1.86 Max: 5.19
Current: 2.11
1.03
5.19
Quick Ratio 1.19
HSKA's Quick Ratio is ranked lower than
78% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. HSKA: 1.19 )
Ranked among companies with meaningful Quick Ratio only.
HSKA' s 10-Year Quick Ratio Range
Min: 0.56  Med: 1.03 Max: 4.4
Current: 1.19
0.56
4.4
Days Inventory 94.24
HSKA's Days Inventory is ranked lower than
57% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.06 vs. HSKA: 94.24 )
Ranked among companies with meaningful Days Inventory only.
HSKA' s 10-Year Days Inventory Range
Min: 82.09  Med: 107.93 Max: 163.18
Current: 94.24
82.09
163.18
Days Sales Outstanding 44.65
HSKA's Days Sales Outstanding is ranked higher than
76% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. HSKA: 44.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSKA' s 10-Year Days Sales Outstanding Range
Min: 14.6  Med: 55.30 Max: 77.96
Current: 44.65
14.6
77.96

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.80
HSKA's Dividend Yield is ranked lower than
78% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. HSKA: 0.80 )
Ranked among companies with meaningful Dividend Yield only.
HSKA' s 10-Year Dividend Yield Range
Min: 0.76  Med: 2.22 Max: 3.73
Current: 0.8
0.76
3.73
Yield on cost (5-Year) 0.80
HSKA's Yield on cost (5-Year) is ranked lower than
77% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. HSKA: 0.80 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
HSKA' s 10-Year Yield on cost (5-Year) Range
Min: 0.76  Med: 2.22 Max: 3.73
Current: 0.8
0.76
3.73
Share Buyback Rate -6.30
HSKA's Share Buyback Rate is ranked lower than
54% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.70 vs. HSKA: -6.30 )
Ranked among companies with meaningful Share Buyback Rate only.
HSKA' s 10-Year Share Buyback Rate Range
Min: 1.8  Med: -3.70 Max: -29.6
Current: -6.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.96
HSKA's Price/Tangible Book is ranked lower than
62% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.24 vs. HSKA: 5.96 )
Ranked among companies with meaningful Price/Tangible Book only.
HSKA' s 10-Year Price/Tangible Book Range
Min: 0.3  Med: 2.16 Max: 261.43
Current: 5.96
0.3
261.43
Price/Projected FCF 4.28
HSKA's Price/Projected FCF is ranked lower than
79% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. HSKA: 4.28 )
Ranked among companies with meaningful Price/Projected FCF only.
HSKA' s 10-Year Price/Projected FCF Range
Min: 0.57  Med: 0.97 Max: 20.11
Current: 4.28
0.57
20.11
Price/Median PS Value 3.40
HSKA's Price/Median PS Value is ranked lower than
97% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. HSKA: 3.40 )
Ranked among companies with meaningful Price/Median PS Value only.
HSKA' s 10-Year Price/Median PS Value Range
Min: 0.23  Med: 1.19 Max: 18.7
Current: 3.4
0.23
18.7
Price/Graham Number 4.43
HSKA's Price/Graham Number is ranked lower than
84% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. HSKA: 4.43 )
Ranked among companies with meaningful Price/Graham Number only.
HSKA' s 10-Year Price/Graham Number Range
Min: 0.19  Med: 1.56 Max: 25.88
Current: 4.43
0.19
25.88
Earnings Yield (Greenblatt) (%) 2.35
HSKA's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. HSKA: 2.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HSKA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.6  Med: 4.20 Max: 20.7
Current: 2.35
0.6
20.7
Forward Rate of Return (Yacktman) (%) -1.11
HSKA's Forward Rate of Return (Yacktman) (%) is ranked lower than
77% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.53 vs. HSKA: -1.11 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HSKA' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -86.8  Med: -2.90 Max: 7.5
Current: -1.11
-86.8
7.5

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 110 121 134 149
EPS($) 0.55 0.75 0.95 1.20
EPS without NRI($) 0.55 0.75 0.95 1.20

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Heska Corp was founded as Paravax, Inc. in 1988 and conducted research on vaccines to prevent infections by parasites. The Company develops, manufactures, markets, sells and supports veterinary products. The Company's core focus is on the canine and feline companion animal health markets where it provides high value products. The Company's business is comprised of two reportable segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment includes mainly for canine and feline use, blood testing instruments and supplies as well as single use products and services such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. These products are sold directly to veterinarians by the Company as well as through distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment includes private label vaccine and pharmaceutical production, mainly for cattle but also for other animals including small mammals. All OVP products are sold by third parties under third party labels. It provides line of veterinary diagnostic and other instruments. Its line of veterinary instruments includes the following: Blood Chemistry; Hematology; Blood Gases and Electrolytes; and IV Pumps. The DRI-CHEM 4000 Veterinary Chemistry Analyzer is a robust system that uses dry slide technology for blood chemistry and electrolyte analysis and has the ability to run 22 tests at a time with a single blood sample. The HEMATRUE Veterinary Hematology Analyzer is a blood analyzer that measures such key parameters as white blood cell count, red blood cell count, platelet count and hemoglobin levels in animals. The Element POC Blood Gas & Electrolyte Analyzer is a handheld, wireless analyzer which delivers rapid blood gas, electrolyte, metabolite, and basic blood chemistry testing. EPOC features test cards with room temperature storage which can provide results with less than 100 µL of sample as well as WiFi and Bluetooth connectivity. The VET/IV 2.2 infusion pump is a compact, affordable IV pump that allows veterinarians to easily provide regulated infusion of fluids, drugs or nutritional products for their patients. Allergy is common in companion animals, and it has been estimated to affect approximately 10% to 15% of dogs. The Company sells kits to conduct blood testing using its ALLERCEPT Definitive Allergen Panels to third-party veterinary diagnostic laboratories outside of the United States. It has veterinary diagnostic laboratories in Loveland, Colorado and Fribourg, Switzerland which both provide blood testing using its ALLERCEPT Definitive Allergen Panels. Its competitors include: IDEXX Laboratories, Inc., Abaxis, Inc. and Synbiotics Corporation. The Company may be or subject to extensive regulation by governmental authorities in the United States, including the USDA and the FDA, and by similar agencies in other countries.
» More Articles for HSKA

Headlines

Articles On GuruFocus.com
My 5 Favorite High Beta Health Care Dividend Stocks Aug 02 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
Heska Corporation: Strong Balance Sheet and Dividend Yield Do Not Compensate for Difficult Business Dec 13 2012 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 5,000 Shares Jun 01 2010 
Heska Corp. (HSKA) CEO Robert B Grieve buys 6,500 Shares May 21 2010 
Weekly CFO Buys Highlight: ZixIt, Global Defense Technology and Systems, FelCor Lodging Trust, Heska Mar 07 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 1,000 Shares Mar 01 2010 
Weekly CFO Buys Highlight: Heska Corp., Apollo Investment Corp., EXACT Sciences Corp., Innospec Inc. Feb 28 2010 
Heska Corp. (HSKA) President and COO Michael J Mcginley buys 12,290 Shares Feb 26 2010 

More From Other Websites
HESKA CORP Financials Aug 20 2015
10-Q for Heska Corp. Aug 10 2015
HESKA CORP Files SEC form 10-Q, Quarterly Report Aug 07 2015
Will Heska (HSKA) Continue to Surge Higher? - Tale of the Tape Aug 05 2015
Why Heska Corporation (HSKA) Could Be an Impressive Growth Stock - Tale of the Tape Aug 04 2015
HESKA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 29 2015
Heska beats 2Q profit forecasts Jul 29 2015
Heska beats 2Q profit forecasts Jul 29 2015
Heska Reports Financial Results for the Second Quarter of 2015 Jul 29 2015
Heska Announces Veterinary Market's first and only point of care Analyzer for TSH, Total T4, and... Jul 28 2015
Webcast Alert: Heska Announces Second Quarter 2015 Earnings Conference Call Webcast Jul 28 2015
Webcast Alert: Heska Announces Second Quarter 2015 Earnings Conference Call Webcast Jul 23 2015
Heska Set to Join Russell 3000 Index and Russell Global Index Jun 18 2015
Heska to Present at Stifel Dental & Veterinary Conference May 20 2015
HESKA CORP Files SEC form 10-Q, Quarterly Report May 14 2015
HESKA CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 08 2015
Heska meets 1Q profit forecasts May 07 2015
Heska meets 1Q profit forecasts May 07 2015
HESKA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 07 2015
Heska Reports 10% Revenue Growth, $0.09 Per Share for the First Quarter of 2015 May 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK